Investing.com - Monopar Therapeutics (NASDAQ: MNPR) reported first quarter EPS of $-0.220, $0.01 worse than the analyst estimate of $-0.210. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.
Monopar Therapeutics's stock price closed at $2.690. It is up 0% in the last 3 months and up 7.170% in the last 12 months.
Monopar Therapeutics saw positive EPS revisions and negative EPS revisions in the last 90 days. See Monopar Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Monopar Therapeutics's Financial Health score is "weak performance".
Check out Monopar Therapeutics's recent earnings performance, and Monopar Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar